Cargando…

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database

BACKGROUND: Medication-related osteonecrosis of the jaw is a serious adverse event associated with bone-modifying agents, such as injectable bisphosphonate (zoledronic acid) and the anti-receptor activator of nuclear factor-κB ligand antibody (denosumab). OBJECTIVE: This study aims to evaluate and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Shiori, Ikesue, Hiroaki, Satake, Riko, Inoue, Misaki, Yoshida, Yu, Tanaka, Mizuki, Matsumoto, Kiyoka, Wakabayashi, Wataru, Oura, Keita, Muroi, Nobuyuki, Hashida, Tohru, Iguchi, Kazuhiro, Nakamura, Mitsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712889/ https://www.ncbi.nlm.nih.gov/pubmed/35933498 http://dx.doi.org/10.1007/s40801-022-00324-4

Ejemplares similares

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
por: Matsumoto, Kiyoka, et al.
Publicado: (2020)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
por: Satake, Riko, et al.
Publicado: (2021)

Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2020)

Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database
por: Inoue, Misaki, et al.
Publicado: (2021)

Author Correction: Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database
por: Inoue, Misaki, et al.
Publicado: (2022)

Gentamicin-induced hearing loss: A retrospective study using the Food and Drug Administration Adverse Event Reporting System and a toxicological study using drug−gene network analysis
por: Tanaka, Mizuki, et al.
Publicado: (2021)

Denosumab Related Osteonecrosis of Jaw: a Case Report
por: de Sales Lima, Marco Vinícius, et al.
Publicado: (2018)

A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma
por: Howie, R. Nicole, et al.
Publicado: (2015)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
por: Limones, Alvaro, et al.
Publicado: (2020)

Platelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws
por: Sarkarat, Farzin, et al.
Publicado: (2014)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Zoledronate‐Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma
por: Lundberg, A.P., et al.
Publicado: (2016)

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw
por: Vidal-Gutiérrez, Ximena, et al.
Publicado: (2017)

Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database
por: Nakao, Satoshi, et al.
Publicado: (2020)

An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid
por: de Alexandria Santos, Danila S., et al.
Publicado: (2020)

Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
por: Alsalih, Aya, et al.
Publicado: (2021)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Zoledronate treatment duration is linked to bisphosphonate‐related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis
por: Messer, Jonathan G., et al.
Publicado: (2019)

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
por: Yamaoka, Kenta, et al.
Publicado: (2022)

384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection
por: Bricca, Romain, et al.
Publicado: (2019)

Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
por: Wick, Alexander, et al.
Publicado: (2021)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Geranylgeraniol Restores Zoledronic Acid-Induced Efferocytosis Inhibition in Bisphosphonate-Related Osteonecrosis of the Jaw
por: Chen, Xin, et al.
Publicado: (2021)

Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid
por: Marín-Fernández, Ana-Belén, et al.
Publicado: (2015)

THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis
por: Ekpe, Victor, et al.
Publicado: (2023)

Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
por: Nakao, Satoshi, et al.
Publicado: (2021)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases
por: Tofé, Victoria I., et al.
Publicado: (2020)

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case
por: Qaisi, Mohammed, et al.
Publicado: (2016)

A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva(®)) Related Osteonecrosis of the Jaw: A Retrospective Study
por: Assili, Zineb, et al.
Publicado: (2021)

A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw
por: Bullock, George, et al.
Publicado: (2022)

Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation
por: Moradi, Saeed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_up2iqqrgk14ban2l0339ke4ebm